Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome

Next Previous
Trial Profile

A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anakinra (Primary) ; Siltuximab (Primary) ; Tocilizumab (Primary)
  • Indications Acute hypoxia; COVID 2019 infections; Cytokine release syndrome; Respiratory insufficiency; SARS-CoV-2 acute respiratory disease
  • Focus Therapeutic Use
  • Acronyms COV-AID

Most Recent Events

  • 15 Jul 2021 Status changed from active, no longer recruiting to completed.
  • 01 Mar 2021 Planned End Date changed from 1 Mar 2021 to 12 Apr 2021.
  • 14 Dec 2020 For Hypoxic-respiratory-failure and respiratory-insufficiency narrower term is ARDS, so I have added ARDS.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top